Cinctive Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,731	Closed	-$681K	–	497
2025 Q2	$681K	Sell	18,731 -58,530	-76%	-$2.11M	0.04%	298
2025 Q1	$2.8M	Buy	77,261 +14,301	+23%	+$595K	0.21%	137
2024 Q4	$2.65M	Buy	62,960 +47,058	+296%	+$2.33M	0.13%	195
2024 Q3	$883K	Sell	15,902 -110,779	-87%	-$5.64M	0.05%	298
2024 Q2	$5.21M	Buy	126,681 +14,930	+13%	+$637K	0.25%	138
2024 Q1	$5.22M	Buy	111,751 +13,700	+14%	+$646K	0.24%	127
2023 Q4	$4.69M	Buy	+98,051	New	+$3.8M	0.31%	107
2022 Q2	–	Sell	-89,692	Closed	-$6.51M	–	616
2022 Q1	$6.51M	Buy	89,692 +15,936	+22%	+$1.11M	0.24%	140
2021 Q4	$6.2M	Buy	73,756 +14,927	+25%	+$1.21M	0.27%	115
2021 Q3	$5.31M	Buy	58,829 +30,118	+105%	+$2.72M	0.26%	124
2021 Q2	$2.74M	Buy	28,711 +13,756	+92%	+$1.43M	0.13%	233
2021 Q1	$1.7M	Buy	14,955 +9,008	+151%	+$1.23M	0.1%	280
2020 Q4	$823K	Sell	5,947 -28,102	-83%	-$3.33M	0.07%	286
2020 Q3	$2.8M	Sell	34,049 -4,059	-11%	-$336K	0.25%	163
2020 Q2	$2.98M	Sell	38,108 -21,925	-37%	-$1.45M	0.34%	121
2020 Q1	$2.67M	Sell	60,033 -73,568	-55%	-$3.82M	0.59%	64
2019 Q4	$5.71M	Buy	+133,601	New	+$5.51M	0.6%	74